Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediniceWAR:ICE -1.65%25 Buyback Yield % is 0.00 as of Jul. 19, 2026. GuruFocus rates WAR:ICE with a GF Score™ of 25/100 and a GF Value™ of zł0.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 348 Medical Devices & Instruments companies, Medinice ranks worse than 287356.03% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Medinice's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:ICE vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Medinice's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinice Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinice's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Medinice's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinice (WAR:ICE) has a Buyback Yield % of 0.00 as of Jul. 19, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Medinice and its competitors. According to the industry distribution chart, Medinice ranks #999999 out of 348 companies in the Medical Devices & Instruments industry.
Is Medinice's Buyback Yield % too high?
Medinice's current Buyback Yield % is 0.00. Based on the distribution chart, Medinice ranks #999999 out of 348 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medinice has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medinice's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medinice ranks #999999 out of 348 companies for Buyback Yield %. This places Medinice in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Medinice and its competitors. Medinice's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinice stock overvalued right now?
Based on GuruFocus' analysis, Medinice (WAR:ICE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.99, compared to a current price of zł71.60 — trading 7132.3% above its estimated fair value. The current Buyback Yield % is 0.00. Medinice's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Medinice (WAR:ICE), the current Buyback Yield % is 0.00 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinice (WAR:ICE) Overvalued in 2026?
Based on GuruFocus' analysis, Medinice stock appears to be overvalued.
The current stock price of zł71.60 is trading 7132.3% above its estimated GF Value™ of zł0.99.
GuruFocus considers Medinice to be Significantly Overvalued.
Key valuation signals for WAR:ICE:
Buyback Yield %: 0.00
GF Value™: zł0.99 vs. price of zł71.60 (7132.3% above fair value)
No single metric tells the full story. See the WAR:ICE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinice SA is a Polish company operating in the MedTech industry. The company is engaged in creating, developing and commercializing solutions in the field of medicine, in particular, cardiology and cardio surgery. Its portfolio includes close around 12 projects including CathAIO, an electrode with universal diagnostic, electrophysiological, haemodinamic and biohemic functions and can be used for RF ablation; cryoapplicator, for minimally invasive cardiosurgical cryoablation; Med-iConsole allows to reduce the need to use multiple computer devices during electrophysiological treatment; Minimax and Pacepress.
25GF Score
Get the complete analysis for WAR:ICE
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:ICE has been successfully added to your 
